The IGF-I receptor (IGF-IR) has an important role in malignant disease and is the target of several drugs presently in clinical trials. Gene therapy has been explored as cancer treatment, mainly for delivery of genes that induce cell death or enhance the immunological response to cancer. Previously, we have shown that the implantation of autologous bone-marrow stromal cells producing a soluble form of IGF-IR (sIGFIR) inhibited experimental liver metastasis of several tumor types in mice. Here, we evaluated the utility of adenovirus-based gene delivery for generating therapeutically effective plasma levels of this decoy. We constructed a third generation gutless adenovirus expressing sIGFIR and found that HEK-293 cells transduced by this, but not control adenoviruses, secreted soluble receptor protein that blocked IGF-I-induced tumor cell migration, proliferation and survival in vitro. Following virus injection in vivo, viral DNA was detectable by PCR in several host organs, particularly the liver, and this resulted in the production of measurable sIGFIR plasma levels for up to 21 days post injection. In mice producing virus-encoded sIGFIR, experimental liver metastasis was inhibited, indicating that sIGFIR levels were therapeutically effective. The results show that adenovirus-based delivery of inhibitory soluble proteins can provide an effective anticancer strategy.
INTRODUCTION
The ability of cancer cells to metastasize remains the greatest challenge to the management of malignant disease. The liver is a major site of metastasis for some of the most prevalent human malignancies, particularly carcinomas of the gastro-intestinal tract. At present, surgical resection is the only curative option for liver metastases but its success rate is partial, producing a 25-40% 5-year disease-free survival rate for malignancies such as colorectal carcinoma. 1 There is, therefore, a need for novel, rationally designed therapeutic strategies that can specifically target molecular mediators of liver metastasis and improve these cure rates.
We and others have identified the IGF-I receptor (IGF-IR) as a critical regulator of the liver-colonizing potential of metastatic tumor cells (reviewed in Samani et al. 2 ). IGF-IR is synthesized as a polypeptide chain of 1367 amino acids that is glycosylated and proteolytically cleaved into a-and b-subunits that dimerize to form a heterotetrameric receptor tyrosine kinase consisting of two 130-135 kDa a and two 90-95 kDa b chains, with several a-a and a-b disulfide bridges. 3 The ligand binding domain is on the extracellular a subunits, while the b subunits consist each, of an extracellular portion linked to the a subunit through disulfide bonds, a transmembrane domain and a cytoplasmic portion with a kinase domain and several critical tyrosines and serines involved in the transmission of ligand-induced signals. 4, 5 The major IGF-IR ligands are IGF-I and IGF-II. Both are produced mainly in the liver and bind IGF-IR with high affinities that exceed that of insulin by a 100-fold. 5 IGF-IR has been identified as a cell survival factor and mediator of malignant progression and has been validated as a target for anticancer therapy (reviewed in Samani et al. 2 and Sachdev and Yee 6 ). Several drugs that target the IGF-IR, including anti-IGF-IR antibodies and kinase inhibitors have already advanced into clinical trials with early indications of efficacy as single modalities or in combination with other drugs. 7, 8 However, targeting the IGF-I system in vivo poses several challenges: (i) Owing to the high degree of homology between the IGF-I and insulin receptors (IRs), drugs that target the IGF axis may also affect the IR/insulin axis with undesirable effects on glucose and lipid metabolism, (ii) inhibition of IGF-I signaling may result in altered serum growth hormone levels, leading to insulin insensitivity and could potentially cause a reduction in pancreatic insulin production and diabetes, (iii) The use of antibody-based therapy may result in antibody-dependent cellmediated cytotoxicity reactions leading to hematological toxicity, as observed in some trials. Furthermore, some tumors also express isoform A of the IR that can bind IGF-II with high affinity and this may provide an alternate survival mechanism for cancer cells whose IGF-IR has been neutralized by antibody treatment or kinase inhibitors. and reduce their bioavailability to the cognate receptor in a highly specific manner. [10] [11] [12] This has recently been demonstrated with the VEGFR1/VEGFR2-Fc decoy receptor (the VEGF-Trap) that is currently in clinical trials as an antiangiogenic, anticancer drug. 13 The utility of decoy receptors for treatment of malignant disease can be optimized through the use of vehicles that can deliver therapeutically effective concentrations of the soluble receptor in a sustained manner into the tumor site. Gene therapy offers one strategy for sustained delivery of genetic information into a target cell and adenovirus-based vectors are still the preferred gene transfer vehicle because they are relatively easy to produce, efficient and able to transduce postmitotic cells. Several obstacles such as toxicity and the induction of host-immune responses that limit the duration of transgene expression have hampered the clinical development of adenovirus-based therapy. Improvements to adenovirus particles in recent years have addressed some of these obstacles. They include the construction of fully viral genedeleted ('gutted') adenovectors, also known as helper-dependent (HD) adenovectors (HD-AdV) that are reasonably free of helper virus contamination. Third generation adenovectors have a significantly reduced vector toxicity because they do not encode any viral genes and could extend transgene expression for periods exceeding 1 year in a variety of tissues, including the liver. [14] [15] [16] The virus particle is relatively stable and the vector possesses a very large transport capacity (up to 37 kb) that allows for the delivery of multiple copies of the gene of interest including complex promoters and other regulatory sequences. Furthermore, because the vector genome is retained in the cell as a stable extra chromosomal element after transduction, the risk of insertional mutagenesis, frequently associated with integrative vectors such as retrovirus-based vectors, is minimal. 17 The use of HD-AdV for the delivery of genetic information coding for soluble peptides has been reported. For example, long-term production of plasma detectable levels of the apolipoprotein A, a1-antitrypsin and coagulation factor VIII for several months in the absence of toxicity has been achieved following the injection of HD-AdV encoding the genes for these therapeutic proteins. 16, 18, 19 We previously reported that liver-metastasizing lung carcinoma cells genetically engineered to produce a 933-amino-acid soluble peptide spanning the entire extracellular domain of the IGF-IR (soluble form of IGF-IR (sIGFIR)) lost IGF-IR signaling and all IGF-IRregulated functions, and failed to produce liver metastases in a high proportion of mice, resulting in markedly increased longterm, disease-free survival. 20 Subsequently, using a cell-based approach for the sustained delivery of this peptide, we have shown that animals implanted with autologous bone marrowderived stromal cells, engineered to produce the soluble receptor, had plasma measurable levels of the protein and that it acted as a decoy, binding circulating IGF-I and thereby likely reducing its bioavailability in the circulation. As a consequence, liver metastasis of three different carcinoma cell types was markedly reduced due to increased tumor cell apoptosis, reduced tumor proliferation and reduced angiogenesis. 21 In the present study, we utilized third generation (gutless) AdV particles that have been genetically modified to express the soluble IGF-IR. We used to advantage, the well documented livertropism of these particles and their propensity to transduce normal liver cells when inoculated intravenously (i.v.) 14, 16 to initiate sIGFIR production and secretion by normal liver cells. We asked whether the virally transduced cells could secrete therapeutically relevant plasma levels of the peptide and as a consequence, inhibit the growth of experimental hepatic metastases.
MATERIALS AND METHODS Cells
Lewis lung carcinoma subline H-59 cells were used for all the experiments. Their origin and metastatic properties were described in detail previously. 22 The HEK-293FLPe cells were used to propagate the gutless virus. 23 The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum and 2 mM glutamine. HEK-293FLPe were kept under selective pressure using 1.5 mg ml À 1 puromycin.
Mice
All animal experiments were performed in C57Bl/6 female mice aged 8-12 weeks (Charles River, St Constant, QC, Canada). All the procedures used were approved by the McGill University Animal Care committee.
Construction and production of gutless AdV expressing soluble IGF-IR
To produce a gutless AdV encoding sIGFIR, the strategy previously described for the production of a mouse dystrophin-encoding virus 24, 25 was used. Briefly, a plasmid (pCB-sIGF1R) encoding a unique NotI site, a DNA stuffer of 10 kb derived from the human dystrophin complementary DNA, the soluble IGF-1R expression cassette regulated by the hybrid cytomegalovirus enhancer/b actin promoter (CB) and a unique AscI site was first constructed by replacing a MluI/SphI 4 kb DNA fragment of the pCBDysFl plasmid 25 with a complementary DNA fragment corresponding to the first 2844 nucleotides of the human IGF-IR RNA. 20, 21 To generate the gutless AdV, pCB-sIGFIR was then digested at the NotI/AscI sites and the fragment self ligated to generate a larger fragment encoding two copies of the soluble IGF-1R complementary DNA as described previously 24, 25 (see diagram in Figure 1a ). To produce virus particles, 293FLPe cells 23 were transfected with the vector using Lipofectamine (Invitrogen, Burlington, Ontario, Canada) and the gutless AdV amplified by coinfection with a helper adenovirus as described previously. 23, 26 Purified gutless virus was obtained following two consecutive CsCl gradient centrifugations and the viral titer (physical particles per ml) was determined based on optical density measurement at 260 nm. 27 Helper virus contamination levels as determined by a plaque assay ranged from 0.5-3 infectious particles per 100 physical particles of virus stock.
Western blotting
Western blotting was performed on serum-free (SF)-conditioned medium (CM) derived from HD-CBsIGFIR or control HD-CBGFP-transduced HEK293 cells. The cells, cultured to 90% confluency in 5% fetal bovine serumDulbecco's modified Eagle's medium were transduced at a multiplicity of infection of 5 in the presence of helper virus, used at the same multiplicity of infection and incubated for 1 h in serum containing medium. The cells were then washed with SF medium, incubated for 72 h in fresh SF medium that was then harvested and concentrated 60-fold. Proteins (40 mg per lane) were resolved on 6% SDS-polyacrylamide gels under reducing conditions and immunoblotting performed as we described previously, 20 using a rabbit polyclonal antibody to human IGF-IR (Santa Cruz, Santa Cruz, CA, USA) diluted 1:600 and peroxidase-conjugated goat anti-rabbit IgG (Cedarlane, Hornby, Ontario, Canada) diluted 1:10000. Protein bands were visualized using the enhanced chemiluminescence system (ECL Prime, Roche, Basel, Switzerland).
Real-time PCR
Mice were killed 72 h following i.v. inoculation of 1.08 Â 10 12 HD-CBsIGFIR particles, organs harvested and snap frozen, and the DNA extracted by overnight digestion at 50 1C in 0.5 ml lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM ethylenediaminetetraacetic acid, 0.2% SDS, 200 mM NaCl) containing 20 mg ml À 1 proteinase K, followed by phenol/chloroform extraction and isopropanol precipitation. The DNA was washed with 70% ethanol, dried and resuspended in TE (10 mM Tris-HCl pH 8, 1 mM ethylenediaminetetraacetic acid) buffer. PCR was carried out using primers specific for the CB promoter region of HD-CBsIGFIR particles (forward-5 0 -CCCACTTGGCAGTA-CATCAA-3 0 , reverse-5 0 -ATGGGGAGAGTGAAGCAGAA-3 0 ) and for the murine adipsin gene (forward-
0 ) that served as a DNA input control. To quantify vector and adipsin DNA content, real-time PCR reactions were performed in two separate tubes, both of which contained DNA extracted from the same sample. PCR was performed in a LightCycler (Roche Applied Science, Laval, Quebec, Canada) using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) and the amplification conditions described in detail previously. 28 The copy number (CB primers) was determined using a standard curve that was generated by spiking 100 ng of untreated liver DNA with known amounts of plasmid encoding the CB promoter (pCB-LacZ). All the data were normalized to the amount of adipsin DNA that was determined using a standard curve generated from normal mouse liver DNA.
Immunohistochemistry
Mice were injected i.v. with 1.72 Â 10 11 HD-CBGFP or 1.08 Â 10 12 HD-CBsIGFIR particles and livers snap frozen 48 h later. To detect green fluorescent protein (GFP) protein in transduced liver cells, 6 mm cryostat sections were prepared, permeabilized in a 0.1% Triton solution, washed three times in phosphate-buffered saline and incubated in blocking buffer (1% fetal bovine serum, 1% bovine serum albumin in phosphate-buffered saline) for 15 min. A rabbit polyclonal antibody to the GFP protein (Abcam, Cambridge, MA, USA) diluted 1:200 in the same buffer was added for an overnight incubation at 4 1 C, followed by a 1-h incubation at room temperature with an Alexa Fluor 568 goat anti-rabbit secondary antibody (Invitrogen Probes, Invitrogen Canada, Burlington, ON) diluted 1:200 in a solution containing also a 1:1000 dilution of DAPI. The sections were washed, mounted with the GOLD anti-fade reagent (Invitrogen) and analyzed with a Carl Zeiss Axiophot microscope equipped with Epifluorescence (Carl Zeiss Canada, Toronto, Ontario, Canada) and a Northern Eclipse image analysis station. To identify liver cells expressing the human sIGFIR protein, the sections were first incubated for 18 h at 4 1C with a mouse monoclonal antibody that recognizes human (but not murine) IGF-IR (Mab aIR3, EMD Millipore, Gibbstown, NJ, USA) at a dilution of 1:25 followed by Alexa Fluor 568 goat anti-rabbit secondary antibody diluted 1:500 as above, and the sections analyzed using a Carl Zeiss LSM 510 Meta, confocal microscope equipped with a Zen image analysis station. Sections derived from non-injected mice and sections from virus-injected mice incubated with the secondary antibody only were used as controls, as indicated.
Enzyme linked immunosorbent assay
Plasma concentrations of sIGFIR were quantified using the human IGF-I R DuoSet enzyme linked immunosorbent assay (ELISA) Development Systems (R&D System, Minneapolis, MN, USA). In all the experiments, plasma obtained from control, untreated mice were used to establish baselines. Mice injected with control virus HD-CBGFP were used as specificity controls.
Anoikis assay
Anoikis was measured as we described in detail previously. 29 Briefly, tumor cells (2.5 Â 10 5 per well) were plated in 24-well plates that were precoated with 10 mg ml À 1 PolyHEMA (Sigma-Aldrich Canada, Oakville, ON) to prevent their attachment. They were then incubated at 37 1 C for 48 h in the presence of serum or SF medium containing 10 ng ml À 1 IGF-I, with or without concentrated CM derived from HD-CBsIGFIR-transduced HEK-293 cells that contained the sIGFIR protein and was diluted to deliver the indicated protein concentration. Concentrated CM derived from HD-CBGFP-transduced HEK-293 cells was used as control. At the end of the incubation period, apoptosis was analyzed using the In Vivo Cell Death Detection-RED staining kit (Roche Canada, Mississauga, ON), as per the manufacturer's instructions.
Invasion assay
Invasion was measured using a real-time, electrical-impedance-based technique utilizing the automated xCELLigence system (Roche Canada). The xCELLigence instrument measures changes in electrical impedance at an electrode/cell interphase, as a population of (malignant) cells invades a Matrigel layer and migrates to a lower chamber of a Boyden-chamber system. The impedance is displayed as a dimensionless parameter termed cell-index that is directly proportional to the total area of tissue-culture well that is covered by cells, as described and demonstrated by others. 17, 30 Tumor H-59 cells (in the upper chamber) were plated in wells (5 Â 10 4 cells per well) that were precoated with the Matrigel (BD Biosciences, Mississauga, Ontario, Canada) at a concentration predetermined to allow optimal invasion (1:40 dilution of Matrigel stock). They were then placed on top of a lower chamber containing 50 ng ml À 1 IGF-I, to which the CM from HD-CBsIGFIR-transduced HK-293 cells that contained the indicated protein concentration was (or was not) added. The cells were incubated at 37 1 C for 48 h and cell index registered as a function of time.
Proliferation assay
Proliferation was also measured using the xCELLigence system (see above). H-59 cell were cultured for 4 h at 37 1 C in 10% fetal calf serum-containing RPMI medium at a concentration of 1 Â 10 4 cells per well in xCELLigence E-plates (Roche Canada). The medium was replaced with 20 ml SF RPMI medium for a 24-h incubation and 10 ng ml À 1 IGF-I then added, with or without CM from HD-CBsIGFIR-transduced HEK-293 cells or control, SF medium. Proliferation was monitored continuously for 48 h.
Experimental metastasis assay
Experimental liver metastases were generated by the injection of 10 5 H-59 tumor cells via the intrasplenic/portal route, 20 9 or 23 days post i.v. injection of the virus. The number of tumor cells to be injected was determined based on preliminary dose-response analyses and selected to produce a quantifiable number of hepatic metastases within 14-21 days post tumor inoculation, at which time the animals were euthanized. Visible metastases on the surfaces of the livers were enumerated and sized immediately after liver removal with the aid of a stereomicroscope, as we have previously described. 20 
Statistical analysis
The student's t-test was used for analysis of in vitro data and the nonparametric Mann-Whitney test for the analysis of metastasis data.
RESULTS
Gutless adenovirus particles expressing sIGFIR (HD-CBsIGFIR) and control, GFP-expressing particles (HD-CBGFP) were constructed as illustrated in Figure 1a and their ability to engineer the production of a soluble IGF-IR protein was first tested in vitro using HEK-293 cells. The cells were infected with HD-CBsIGFIR or HD-CBGFP and here we show that IGF-I could rescue these cells from celldetachment-induced apoptosis (anoikis) (Figure 2a) . As shown in Figure 2a , this effect of IGF-I was inhibited when CM proteins obtained from HD-CBsIGFIR, but not from HD-CBGFP-transduced HEK-293 cells were added to the cells. Similarly, the addition of HD-CBsIGFIR/HEK-293-CM inhibited the ability of IGF-I to induce tumor cell proliferation (Figure 2b ) or invasion as measured in a Boyden-chamber type assay (Figure 2c ). The inhibitory effect was specific for IGF-I and was not seen in the presence of 10% fetal calf serum (Figure 2b ), suggesting that in the presence of serum, factors other than IGF-I (for example, platelet-derived growth factor) could stimulate tumor cell proliferation. The inhibitory effect was also dose-dependent (Figure 2a Fetal bovine serum (FBS)-containing medium was used as a positive control. The results are expressed as fold increase in apoptosis relative to cells cultured in FBS that were assigned a value of 1 and are based on two experiments performed in triplicates. Proliferation (b) was measured using 10 4 H-59 cells per well seeded in an xCELLigence E-plate, starved in serum-free medium for 24 h and then incubated (or not) for 48 h with 10 ng ml À 1 IGF-I, with or without concentrated, sIGF-IR containing HEK-293-conditioned media. FBScontaining wells were used as specificity controls. Shown are results of a representative experiment (n ¼ 2) based on triplicate samples and expressed as a cell index that is directly proportional to the total area of the xCELLigence well covered by cells. To measure tumor invasion (c) 5 Â 10 4 H-59 cells were added to the upper wells of xCELLigence CIM-plates that were precoated with Matrigel and placed on top of lower chambers containing (or not) 50 ng ml À 1 IGF-I and with or without the indicated conditioned media proteins at the specified concentrations for a 48-h incubation. Results are based on triplicate measurements in a representative experiment (n ¼ 2) and are expressed as a cell index, as detailed above. *Po0.05, **Po0.02, ***Po0.0001. SF, serum-free medium. Sustained production of sIGFIR in mice infected with the gutless HD-CBsIGFIR adenovirus We next determined whether mice infected with the gutless virus could produce plasma detectable levels of the soluble IGF-IR protein.
Mice were inoculated i.v. with increasing numbers of viral particles, blood was collected at different intervals, thereafter, and plasma sIGFIR levels analyzed by ELISA. Results in Figure 4 show that measurable sIGFIR levels could be detected in the plasma of HD-CBsIGFIR-injected mice, but not in plasma of mice inoculated with HD-CBGFP virus, within 24 h of virus injection. Plasma sIGFIR levels increased proportionally to the viral dose and declined over time, but could be elevated by a second injection of adenovirus 10 days following the initial inoculation, resulting in a sustained level of 100-300 ng ml À 1 for at least 3 weeks (Figure 4) . A fluorescencebased assay to detect neutralizing antibodies against adenovirus particles in the sera of these mice showed only a minor and nonsignificant increase in virus neutralizing activity in sera obtained on day 7, as compared with day 1 post virus injection, but significant virus-neutralizing activity was detectable on day 21 (11 days after the second virus injection, Supplementary Figure 2) . 
DISCUSSION
Adenovirus particles remain the vehicle of choice for therapeutic gene transfer, in particular for gene therapy of cancer. [32] [33] [34] The development of HD-gutless adenoviral particles has markedly improved the potential clinical utility of these vectors by reducing their toxicity and increasing the duration of gene expression. Here, we sought to determine whether an HD-AdV could be used to initiate a sustained production of therapeutically relevant levels of a soluble form of the IGF-IR with antitumorigenic properties. Our results show that within 24 h of HD-CBsIGFIR inoculation, the sIGFIR protein was detectable in mouse plasma and measurable levels persisted and could be maintained for at least 3 weeks (the duration of this study) with an additional virus injection 10 days later. Tumor cells inoculated into the mice within 1-3 weeks post virus injection developed significantly fewer hepatic metastases than vehicle or control virus injected mice, indicating that the secreted levels were sufficient to inhibit tumor growth. We observed that mice injected with HD-CBGFP particles had an increased number of hepatic metastases relative to vehicle-injected controls. While the reason for this increase is not immediately clear, the results do suggest that viral transduction per se, in the absence of production of an inhibitory protein such as sIGFIR may increase the susceptibility of the liver to tumor formation.
It should be noted that because HD-AdV no longer express viral genes, de novo viral protein synthesis does not occur after viral transduction and this greatly reduces the immunogenicity and toxicity of the vector. Nevertheless, capsid proteins were shown to be immunogenic and induce an acute immune response, if the vector is injected at very high doses. 17 In our study, we found that viral particles transduced cells in several organs with the highest viral DNA level detectable in the liver. Expression of the transgene in liver cells could be confirmed by immunohistochemistry. The transduced cells could secrete plasma detectable sIGFIR protein within 24 h of transduction and a second virus injection 10 days later resulted in a further increase in the plasma levels of sIGFIR, measurable 3 days later. Our results also show that following the first virus injection, there was no significant increase in virus neutralizing activity in the sera of injected mice, but this activity increased significantly after the second injection. Together, these results suggest that a humoral immune response to caspid proteins, if it was induced, was not sufficient to eliminate all viral particles injected on day 10, allowing for transduction of additional host cells and an increase in plasma sIGFIR levels. Sustained recombinant protein production by the liver for over a year following HD-AdV treatment has been demonstrated in other preclinical studies. 17 In a previous study, we have shown that mice implanted with autologous bone marrow-derived stromal cells genetically engineered to produce the soluble IGF-IR had reduced tumor growth in the liver and this was attributable to decreased proliferation, increased apoptosis and decreased angiogenesis in tumor micrometastases during the early stages of metastases development. 21 Similar to our findings in that study, we observed here that the inhibitory effect of sIGFIR was optimal when tumor cells were inoculated several days after the initiation of sIGFIR production and could, in fact, be observed even when plasma levels were declining 3-4 weeks post HD-CBsIGFIR injection, suggesting that a sustained production was necessary for the antitumorigenic effect. The results suggest that a period of 'conditioning' of the host microenvironment may have been required for optimal effects. Previously, we have already ruled out a contribution by the host humoral immune response to the soluble receptor. 21 Together, the data suggest that in addition to direct effects that the soluble receptor has on tumor cell survival and growth due to the reduced bioavailability of IGF-I, 21 the sustained presence of sIGFIR:IGF-I complexes may also affect other, host-dependent factors that normally contribute to the formation of hepatic metastases, such as the stromal and inflammatory responses. Previously, we have shown that tumor cell invading the liver initiate a host inflammatory response that promotes tumor cell arrest, intravasation and metastasis, [35] [36] [37] and more recently we reported that these parameters are altered in mice with a sustained liver IGF-I deficiency where tumor growth was inhibited, 38 consistent with the known role of the IGF axis in the regulation of host inflammation and immunity. 39 Changes in IGF-I bioavailability may, therefore, also affect growth of metastases indirectly, by altering the host response to invading tumor cells.
Several clinical trials are presently being conducted with IGF-IR inhibitors as single agents or in combination therapy for cancer. 40 While reports on the utility of anti-IGFIR antibodies have already indicated therapeutic benefit, particularly in combination therapy 41, 42 (reviewed in Gualberto and Pollak 40 ), specifically targeting the IGF-I system in vivo with antibodies or kinase inhibitors is challenging due to the high degree of homology between the IGF-IR and IRs. As a consequence, the use of IGF-IR inhibitors can have undesirable effects on the IR/insulin axis, resulting in disruption of normal glucose and lipid metabolism. 9 The use of a soluble form of the IGF-IR provides an alternative Previously, we have confirmed that circulating sIGFIR had no deleterious effects on the mice and did not affect plasma insulin or glucose levels 21 and similarly, we observed here that HDCBsIGFIR injection had no apparent negative effects on the general health of the mice, as they showed no signs of organ pathology at autopsy, despite confirmed viral transduction of the liver and other organs.
Our results are in accord with those reported by Tseng et al and who used AdV particles expressing a soluble form of the VEGF receptor (Flk1) to engineer a sustained production of this soluble receptor in vivo and observed an antitumorigenic/antimetastatic effect in a pancreatic carcinoma model. 12, 43 In those studies, however, AdV administration was initiated only after tumor inoculation and it is unclear, therefore, what contribution direct viral transduction of the tumor cells has made to the observed antitumorigenic effect. On the other hand, in the present study, AdV administration was initiated, and plasma levels of sIGFIR confirmed, before tumor injection, ruling out possible direct transduction of tumor cells. The results clearly demonstrate, therefore, that host cells can be recruited to act as producers of the therapeutic protein and as a consequence, precondition the mice to resist tumor growth, at least in the liver.
The translational applications of our results remain to be seen. A treatment protocol akin to that used in this study may require the administration of 10 14 -10 15 virus particles per patient and it is unlikely that this vector dose or the method of administration employed in the present study will be practicable in human patients, given the present state of the technology. However, safe and sustained recombinant protein production by the liver were recently demonstrated in non-human primates using HD-AdV titers as low as 10 11 particles per kg and a minimally invasive delivery method referred to as pseudo-hydrodynamic delivery, 30, 44 potentially providing a more promising approach for clinical applications. The use of HD-AdV to deliver soluble proteins has an advantage over the use of autologous bone marrow stromal cells because the same HD-AdV preparation can be used to treat multiple patients while autologous bone marrow-derived cells require an individualized preparation and characterization for each patient.
With further progress in the optimization of noninfectious, nontoxic AdV particles and improved AdV retargeting, the prolonged systemic delivery of sIGFIR through host cell transduction could potentially become a clinically relevant strategy for the prevention of tumor recurrence and metastasis.
